Response of all patients to treatment based on PD-1 inhibitors
| Patient | Pathologic type | Treatment | 8w | 12w | Overall | PD-L1 | MSI |
|---|---|---|---|---|---|---|---|
| LYC | OS | Pembrolizumab | SD | PR | PR | − | MSS |
| WJH | OS | Combined | SD | SD | SD | − | |
| XX | OS | Combined | SD | SD | SD | ||
| ZWY | OS | Combined | PD | PD | PD | − | 5.74 |
| LY | OS | Combined | SD | PD | PD | ||
| ZFL | LPS | Combined | SD | SD | PD | − | |
| WHX | LPS | Combined | SD | SD | SD | − | 7.19 |
| XMC | LPS | Combined | PD | − | |||
| MXW | LPS | Combined | SD | + | 2.7 | ||
| ZX | SS | Pembrolizumab | SD | SD | SD | − | |
| WY | SS | Combined | SD | SD | SD | ||
| TMM | SS | Combined | SD | SD | SD | ||
| DLY | UPS | Combined | PD | PD | PD | ||
| MRH | UPS | Combined | SD | + | 2.56 | ||
| KZP | UPS | Combined | PD | - | 0.9 | ||
| CMJ | RMS | Combined | PD | ||||
| GXS | RMS | Combined | SD | PD | PD | ||
| YHB | CDS | Combined | SD | SD | SD | ||
| LLL | CDS | Combined | SD | PR | PR | 1.71 | |
| SHY | LMS | Pembrolizumab+radiotherapy | PD | PR | PD | + | |
| GJJ | LMS | Combined | SD | SD | SD | − | 4.69 |
| PFL | CCS | Pembrolizumab | PD | ||||
| WB | CCS | Combined | SD | PD | PD | ||
| MYT | MPNST | Combined | SD | SD | PD | − | 4.11 |
OS, osteosarcoma; SS, synovial sarcoma; RMS, rhabdomyosarcoma; CDS, chondrosarcoma; LMS, leiomyosarcoma; CCS, clear cell sarcoma; LPS, liposarcoma; MPNST, malignant peripheral nerve sheath tumor; UPS, undifferentiated pleomorphic sarcoma. Combined treatment (camrelizumab+apatinib).